Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients

Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma represents a considerable treatment option to protect these patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Thümmler, Laura, Lindemann, Monika, Horn, Peter A., Lenz, Veronika, Konik, Margarethe, Gäckler, Anja, Boss, Kristina, Theodoropoulos, Fotis, Besa, Vasiliki, Taube, Christian, Brenner, Thorsten, Witzke, Oliver, Krawczyk, Adalbert, Rohn, Hana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861454/
https://www.ncbi.nlm.nih.gov/pubmed/36680159
http://dx.doi.org/10.3390/v15010119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861454/
https://www.ncbi.nlm.nih.gov/pubmed/36680159
http://dx.doi.org/10.3390/v15010119

Ejemplares similares